Valuation: VISD GP

Market Cap 54.95M 62.74M 50.61M 46.98M 89.21M 5.98B 90.42M 606M 236M 2.94B 236M 230M 10.19B P/E 2024
44.3x
P/E 2025 31.3x
Enterprise Value 55.08M 62.89M 50.73M 47.09M 89.42M 6B 90.63M 607M 236M 2.94B 236M 231M 10.21B EV / Sales 2024
3.3x
EV / Sales 2025 3.04x
Free-Float
99.83%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 36 2024-01-21
Investor Relations Contact - -
Chief Executive Officer - 2022-03-31
Director TitleAgeSince
Chairman - -
Director/Board Member - 2022-03-31
Director/Board Member 51 2023-06-13
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-1.26%+53.37%+47.07% 134B
+1.25%+5.84%+9.57%+41.02% 91.07B
+1.81%+9.53%+1.81%+74.47% 27.34B
-1.31%+0.21%+22.49%+52.79% 23.88B
+0.09%+2.30%-19.07%-23.45% 20.28B
+1.33%+9.99%+18.94%+157.47% 17.55B
-1.79%+1.27%+2.60%+12.56% 15.2B
-0.06%+6.61%+64.01%+129.76% 15.08B
+0.22%+4.12%-14.08%-3.90% 12.63B
Average -0.10%+4.88%+15.52%+54.20% 39.63B
Weighted average by Cap. -0.55%+3.62%+26.25%+49.65%

Financials

2024 2025
Net sales 17.26M 19.71M 15.9M 14.76M 28.02M 1.88B 28.4M 190M 74.06M 923M 74.01M 72.39M 3.2B 22.17M 25.31M 20.42M 18.95M 35.99M 2.41B 36.47M 244M 95.11M 1.19B 95.05M 92.96M 4.11B
Net income 1.4M 1.6M 1.29M 1.2M 2.28M 153M 2.31M 15.49M 6.03M 75.11M 6.02M 5.89M 260M 2.28M 2.6M 2.1M 1.95M 3.7M 248M 3.75M 25.15M 9.79M 122M 9.78M 9.57M 423M
Net Debt 2.58M 2.94M 2.37M 2.2M 4.18M 280M 4.24M 28.39M 11.05M 138M 11.04M 10.8M 477M 125K 143K 115K 107K 203K 13.61M 206K 1.38M 536K 6.68M 536K 524K 23.17M
Logo VISD GP
Founded in 2007, Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, its joint venture Smart Health, dedicated to the roll-out of digital medical testing centres in Saudi Arabia; and Klea Pharmaceuticals, a subsidiary dedicated to the commercialisation of a portfolio of licensed medicines in the Middle East and Africa.
Employees
-